Abstract | OBJECTIVE: METHODS: Athymic, nude mice bearing SCC-1 xenografts were used to comprise 4 treatment groups: (1) control receiving vehicle alone, (2) marimastat alone, (3) cisplatin + radiation in combination and (4) marimastat + cisplatin + radiation in combination. The marimastat was administered at a dose of 8.7 mg/kg/day over a 14-day period via a subcutaneous osmotic pump. The control group received vehicle only via a subcutaneous osmotic pump. Radiotherapy was given in 4 fractions of 8 Gy divided over days 8, 12, 16 and 20 with 4 intraperitoneal doses of cisplatin (3 mg/kg) 1 h before each fraction of radiation. RESULTS: Animals receiving triple treatment had delayed growth, measured as lengthened tumor doubling time, compared to the cisplatin + radiation combination (p = 0.03). Also, compared to control, the triple-treatment group (p = 0.005) had delayed growth in terms of doubling time. Factor VIII immunohistochemistry to assess microvessel density did not demonstrate a reduction in neovascularization between the triple-treatment and cisplatin + radiation combination groups. Statistical analysis failed to demonstrate any significant difference among groups. CONCLUSIONS:
|
Authors | Joni B Skipper, Lacey R McNally, Eben L Rosenthal, Wenquan Wang, Donald J Buchsbaum |
Journal | ORL; journal for oto-rhino-laryngology and its related specialties
(ORL J Otorhinolaryngol Relat Spec)
Vol. 71
Issue 1
Pg. 1-5
( 2009)
ISSN: 1423-0275 [Electronic] Switzerland |
PMID | 18931526
(Publication Type: Comparative Study, Journal Article, Research Support, N.I.H., Extramural)
|
Copyright | Copyright 2008 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Hydroxamic Acids
- Matrix Metalloproteinase Inhibitors
- Protease Inhibitors
- marimastat
- Cisplatin
|
Topics |
- Animals
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Squamous Cell
(blood supply, drug therapy, pathology, radiotherapy)
- Cisplatin
(therapeutic use)
- Female
- Head and Neck Neoplasms
(blood supply, drug therapy, pathology, radiotherapy)
- Hydroxamic Acids
(therapeutic use)
- Matrix Metalloproteinase Inhibitors
- Mice
- Mice, Nude
- Microcirculation
(drug effects, radiation effects)
- Neoplasm Transplantation
- Neovascularization, Pathologic
(pathology)
- Protease Inhibitors
(therapeutic use)
- Transplantation, Heterologous
- Treatment Outcome
|